InvestSMART

Immutep Limited (ASX:IMM)

ALERT: Price-sensitive ASX Announcement for IMM
Current share price for IMM : $0.051 -0.334 (-86.75%)+
Announcement
Release
25 Feb 2026 9:07AM
Price at Release
$0.385
Full Release
download
Summary
The half-yearly report for Immutep Limited, an Australian biotechnology company, covers the financial period ending 31 December 2025. Immutep is focused on developing immunotherapies related to LAG-3 for cancer and autoimmune diseases. The company is advancing its lead product candidate, eftilagimod alfa (efti), through a Phase III clinical trial for non-small cell lung cancer and has several other ongoing trials in different cancer indications. Immutep has entered a strategic collaboration with Dr. Reddy's Laboratories for the development and commercialization of efti outside of North America, Europe, Japan, and Greater China, with an upfront payment of USD 20 million. Financial statements show the company has cash and cash equivalents of AUD 72.7 million at the end of the period, with significant cash inflows from investing activities and a net cash outflow from operating activities. The company reported a net loss for the half-year of AUD 44.9 million, while also detailing movements in equity and reserves.
Key Points
  • Immutep Limited focuses on LAG-3 immunotherapy development.
  • Lead product eftilagimod alfa (efti) is in Phase III trials.
  • Strategic collaboration with Dr. Reddy's for efti outside key markets.
  • Received USD 20 million upfront payment from Dr. Reddy's.
  • Reported a net loss of AUD 44.9 million for the half-year.
  • Cash and cash equivalents were AUD 72.7 million as of December 2025.
  • Significant cash inflows from investing activities.
  • Ongoing trials in various cancer indications and autoimmune diseases.
  • Immutep retains manufacturing rights for efti globally, excluding Greater China.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.